Literature DB >> 15452263

Persistent infection with primate foamy virus type 1 increases human immunodeficiency virus type 1 cell binding via a Bet-independent mechanism.

Cecile Schiffer1, Charles-Henri Lecellier, Abdelkrim Mannioui, Nathalie Felix, Elisabeth Nelson, Jacqueline Lehmann-Che, Marie-Louise Giron, Jean Claude Gluckman, Ali Saib, Bruno Canque.   

Abstract

We report that human T cells persistently infected with primate foamy virus type 1 (PFV-1) display an increased capacity to bind human immunodeficiency virus type 1 (HIV-1), resulting in increased cell permissiveness to HIV-1 infection and enhanced cell-to-cell virus transmission. This phenomenon is independent of HIV-1 receptor, CD4, and it is not related to PFV-1 Bet protein expression. Increased virus attachment is specifically inhibited by heparin, indicating that it should be mediated by interactions with heparan sulfate glycosaminoglycans expressed on the target cells. Given that both viruses infect similar animal species, the issue of whether coinfection with primate foamy viruses interferes with the natural course of lentivirus infections in nonhuman primates should be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452263      PMCID: PMC521848          DOI: 10.1128/JVI.78.20.11405-11410.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

Review 2.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication.

Authors:  Y Bakri; C Schiffer; V Zennou; P Charneau; E Kahn; A Benjouad; J C Gluckman; B Canque
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  Intra- and intercellular trafficking of the foamy virus auxiliary bet protein.

Authors:  Charles-Henri Lecellier; Wim Vermeulen; Françoise Bachelerie; Marie-Lou Giron; Ali Saïb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Cell-type-specific regulation of the two foamy virus promoters.

Authors:  C D Meiering; C Rubio; C May; M L Linial
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Long-term non-progression of HIV-1 in a patient coinfected with HTLV-II.

Authors:  R J Willy; C M Salas; G E Macalino; J D Rich
Journal:  Diagn Microbiol Infect Dis       Date:  1999-12       Impact factor: 2.803

7.  Simian foamy virus infections in a baboon breeding colony.

Authors:  E L Blewett; D H Black; N W Lerche; G White; R Eberle
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

8.  Human foamy virus capsid formation requires an interaction domain in the N terminus of Gag.

Authors:  J Tobaly-Tapiero; P Bittoun; M L Giron; M Neves; M Koken; A Saïb; H de Thé
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 9.  HHV-6 infection in patients with HIV-1 infection and disease.

Authors:  L E Fantry; F R Cleghorn
Journal:  AIDS Read       Date:  1999 May-Jun

10.  Further characterization of equine foamy virus reveals unusual features among the foamy viruses.

Authors:  Charles-Henri Lecellier; Manuel Neves; Marie-Lou Giron; Joelle Tobaly-Tapiero; Ali Saïb
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  8 in total

1.  Restriction of foamy viruses by APOBEC cytidine deaminases.

Authors:  Frédéric Delebecque; Rodolphe Suspène; Sara Calattini; Nicoletta Casartelli; Ali Saïb; Alain Froment; Simon Wain-Hobson; Antoine Gessain; Jean-Pierre Vartanian; Olivier Schwartz
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression.

Authors:  S M Murray; L J Picker; M K Axthelm; M L Linial
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Innate sensing of foamy viruses by human hematopoietic cells.

Authors:  Réjane Rua; Alice Lepelley; Antoine Gessain; Olivier Schwartz
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  In vivo cellular tropism of gorilla simian foamy virus in blood of infected humans.

Authors:  Rejane Rua; Edouard Betsem; Thomas Montange; Florence Buseyne; Antoine Gessain
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

5.  Influence of naturally occurring simian foamy viruses (SFVs) on SIV disease progression in the rhesus macaque (Macaca mulatta) model.

Authors:  Anil Choudhary; Teresa A Galvin; Dhanya K Williams; Joel Beren; Mark A Bryant; Arifa S Khan
Journal:  Viruses       Date:  2013-06-06       Impact factor: 5.048

6.  Centrosomal latency of incoming foamy viruses in resting cells.

Authors:  Jacqueline Lehmann-Che; Noémie Renault; Marie Lou Giron; Philippe Roingeard; Emmanuel Clave; Joelle Tobaly-Tapiero; Patricia Bittoun; Antoine Toubert; Hugues de Thé; Ali Saïb
Journal:  PLoS Pathog       Date:  2007-05-25       Impact factor: 6.823

7.  Dual Simian Foamy Virus/Human Immunodeficiency Virus Type 1 Infections in Persons from Côte d'Ivoire.

Authors:  William M Switzer; Shaohua Tang; HaoQiang Zheng; Anupama Shankar; Patrick S Sprinkle; Vickie Sullivan; Timothy C Granade; Walid Heneine
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

8.  STLV-1 co-infection is correlated with an increased SFV proviral load in the peripheral blood of SFV/STLV-1 naturally infected non-human primates.

Authors:  Sandrine Alais; Amandine Pasquier; Brice Jegado; Chloé Journo; Réjane Rua; Antoine Gessain; Joelle Tobaly-Tapiero; Romain Lacoste; Jocelyn Turpin; Renaud Mahieux
Journal:  PLoS Negl Trop Dis       Date:  2018-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.